Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease

Goyal, Alka; Yeh, Andrew; Bush, Brian R.; Firek, Brian; Siebold, Leah; Rogers, Matthew B.; Kufen, Adam; Morowitz, Michael J.

doi:10.1093/ibd/izx035

Cited by 116 publications

(144 citation statements)

References 43 publications

Supporting

Mentioning

135

Contrasting

Unclassified

Order By: Relevance

“…The clinical response rates of 86.7% and 66.7% (at 1 month and 6 months, respectively), 77.8% (7 of 9 patients), 57.9% (11 of 19 patients), 71% and 42% (at 1 month and 6 months, respectively) have been reported separately in four clinical trials (Cui et al 2015a; Goyal et al 2018; Suskind et al 2015; Vaughn et al 2016). However, how to maintain the long-term response of remodeling microbiota in CD based on FMT is another critical question.…”

Section: Discussionmentioning

confidence: 98%

“…Several pilot studies have shown that FMT could effectively induce clinical response in patients with active CD (Colman and Rubin 2014; Cui et al 2015a; Goyal et al 2018; Suskind et al 2015; Vaughn et al 2016). The clinical response rates of 86.7% and 66.7% (at 1 month and 6 months, respectively), 77.8% (7 of 9 patients), 57.9% (11 of 19 patients), 71% and 42% (at 1 month and 6 months, respectively) have been reported separately in four clinical trials (Cui et al 2015a; Goyal et al 2018; Suskind et al 2015; Vaughn et al 2016).…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown that administration of fecal microbiota transplantation (FMT) could effectively induce clinical response in patients with active CD (Colman and Rubin 2014; Cui et al 2015a; Goyal et al 2018; Suskind et al 2015; Vaughn et al 2016). However, the patients’ clinical response to single FMT is short lived.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease

Zhang

Xiao

et al. 2018

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Increasing evidence has shown that fecal microbiota transplantation (FMT) could be a promising treatment option for Crohn’s disease (CD). However, the frequency of FMT for CD treatment remains unclear. This study aimed to evaluate the optimal timing for administering the second course of FMT to maintain the long-term clinical effects from the first FMT for patients with CD. Sixty-nine patients with active CD who underwent FMT twice and benefited from the first FMT were enrolled in this study. Clinical response, stool microbiota, and urine metabolome of patients were assessed during the follow-up. The median time of maintaining clinical response to the first FMT in total 69 patients was 125 days (IQR, 82.5–225.5). The time of maintaining clinical response to the second FMT in 56 of 69 patients was 176.5 days (IQR, 98.5–280). The fecal microbiota composition of each patient post the first FMT was closer to that of his/her donor. Compared to that of the baseline, patients prior to the second course of FMT showed significant differences in urinary metabolic profiles characterized by increased indoxyl sulfate, 4-hydroxyphenylacetate, creatinine, dimethylamine, glycylproline, hippurate, and trimethylamine oxide (TMAO). This study demonstrated that patients with CD could be administered the second course of FMT less than 4 months after the first FMT for maintaining the clinical benefits from the first FMT. This was supported by the host–microbial metabolism changes in patients with active CD. Trial registration: ClinicalTrials.gov, NCT01793831. Registered 18 February 2013. https://clinicaltrials.gov/ct2/show/NCT01793831?term=NCT01793831&rank=1Electronic supplementary materialThe online version of this article (10.1007/s00253-018-9447-x) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 98%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease

Zhang

Xiao

et al. 2018

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…Unlike the effect of microflora transplantation on recurrent CDI, the results of many studies on FMT in UC are heterogeneous [123][124][125][126][127][128][129][130][131][132] owing to the lack of a standardized process ( Table 2). 9 One study suggests that the microbial imbalance of the CDI + UC recipients is similar to that of CDI-only recipients 140 Thus, the efficacy for FMT treatment in UC is probably attributed to the occurrence of bacterial dysregulation similar to that seen in CDI.…”

Section: Effectiveness Of Fmtmentioning

confidence: 99%

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Guo

Liu

Hao

2020

J of Digest Diseases

179

110

View full text Add to dashboard Cite

Gut microbiota constitute the largest reservoir of the human microbiome and are an abundant and stable ecosystem—based on its diversity, complexity, redundancy, and host interactions This ecosystem is indispensable for human development and health. The integrity of the intestinal mucosal barrier depends on its interactions with gut microbiota. The commensal bacterial community is implicated in the pathogenesis of inflammatory bowel disease (IBD), including ulcerative colitis (UC). The dysbiosis of microbes is characterized by reduced biodiversity, abnormal composition of gut microbiota, altered spatial distribution, as well as interactions among microbiota, between different strains of microbiota, and with the host. The defects in microecology, with the related metabolic pathways and molecular mechanisms, play a critical role in the innate immunity of the intestinal mucosa in UC. Fecal microbiota transplantation (FMT) has been used to treat many diseases related to gut microbiota, with the most promising outcome reported in antibiotic‐associated diarrhea, followed by IBD. This review evaluated the results of various reports of FMT in UC. The efficacy of FMT remains highly controversial, and needs to be regularized by integrated management, standardization of procedures, and individualization of treatment.

show abstract

“…Ananthakrishnan et al [184] have studied the response to antiintegrin biologic therapy in association with the microbiome and have concluded that microbial function and diversity in early stages of therapy might be able to predict its efficacy. Finally, many studies have focused on fecal microbiota transplantation (FMT) [185][186][187][188][189] as a potential therapeutic action versus IBD, but also as a possible irritant [190,191].…”

Section: Microbiome In Ibd: the Meta-paradigmmentioning

confidence: 99%

Systems biology in inflammatory bowel diseases: on the way to precision medicine

Dovrolis

Filidou

Kolios

2019

aog

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are chronic and recurrent inflammatory disorders of the gastrointestinal tract. The elucidation of their etiopathology requires complex and multiple approaches. Systems biology has come to fulfill this need in approaching the pathogenetic mechanisms of IBD and its etiopathology, in a comprehensive way, by combining data from different scientific sources. In combination with bioinformatics and network medicine, it uses principles from computer science, mathematics, physics, chemistry, biology, medicine and computational tools to achieve its purposes. Systems biology utilizes scientific sources that provide data from omics studies (e.g., genomics, transcriptomics, etc.) and clinical observations, whose combined analysis leads to network formation and ultimately to a more integrative image of disease etiopathogenesis. In this review, we analyze the current literature on the methods and the tools utilized by systems biology in order to cover an innovative and exciting field: IBD-omics.

show abstract

Safety, Clinical Response, and Microbiome Findings Following Fecal Microbiota Transplant in Children With Inflammatory Bowel Disease

Cited by 116 publications

References 43 publications

Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease

Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn’s disease

Gut microbiota in ulcerative colitis: insights on pathogenesis and treatment

Systems biology in inflammatory bowel diseases: on the way to precision medicine

Contact Info

Product

Resources

About